News Chart Calliditas Therapeutics AB

Equities

Delayed Nasdaq Stockholm Other stock markets 11:59:51 08/05/2024 BST			5-day change	1st Jan Change
112 ^SEK	+0.18%		+3.04%	-11.88%

05-06	Calliditas Therapeutics' Potential Head and Neck Cancer Treatment Meets Secondary Endpoints	MT
05-06	Calliditas Therapeutics AB Announces Positive Topline Results of Phase 2 Head and Neck Cancer Trial with Lead NOX Inhibitor Candidate, Setanaxib	CI

e639bcc561.CX9fNSK5J4sGaLMMdwWUdEwL7wmYdRVO6iGlrtQ1pDM.WDQGTHTMSd1tI-Q8H0fEJiNKqFDiD3I4gUDtyq1UxkZHFA5mD9Rp22k96g~f92073011a85ae507f4bcb6269f6a806